Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Side_by_Cide: iCASP9-modified T-cells in Allogeneic HSCT
NCT02849886Phase 2Terminated
- Sponsor
- CHU de Besançon
- Start
- Apr 2019
- Primary completion
- Dec 2021
- Countries
- 1
01
Overview
A Phase 2 trial of iCASP9-ΔCD19 T-lymphocytes in hematological malignancies, graft-versus-host disease (GVHD), sponsored by CHU de Besançon. Started Apr 2019; status: terminated.
02
Drugs
iCASP9-ΔCD19 T-lymphocytes
03
Conditions
hematological malignanciesgraft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT02849886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02849886.